John D Roberts MD

Professor of Medicine (Medical Oncology); Medical Director, Adult Sickle Cell Program at Yale-New Haven Hospital

Specialties & Subspecialties

Cancer Center, Yale: Prostate and Urologic Cancers Program | Hematology Program

Medical Oncology

Education & Training

  • M.D., University of Pennsylvania (1976)
  • AB, Harvard University (1982)
  • Resident, University of North Carolina at Chapel Hill , Internal Medicine and Pediatrics (1976 - 1980)
  • Fellow, University of Vermont , Medical Oncology (1982 - 1984)

Patient Care

Accepts New Patients? Yes | Patient Type: Adult | Accepts referrals from patients


Clinical Interests

sickle cell disease; medical oncology phase I trials; urological cancers (prostate, bladder, testicle)


Cancers Treated

Bladder, Prostate, Testes (including Penis)


Board Certifications

  • Hospice & Palliative Medicine, Board Certified (2012)
  • Internal Medicine, Board Certified (1980)
  • Medical Oncology, Board Certified (1985)

Clinical Trials

ConditionsStudy Title
BladderGO29293: A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF MPDL3280A IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER
ProstatePhase II, open label study of the effect of GTx-758 as secondary hormonal therapy on serum PSA and serum free testosterone levels in men with metastatic castration resistant prostate cancer maintained on androgen deprivation therapy
Breast - Female, Colon, Esophagus, Lung, and Melanoma, skin(Novartis Signature) Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 8 ¿ LEE011 for patients with CDK4/6 pathway activated tumors
Bladder, Breast - Female, Breast - Male, Colon, Kidney, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Other Skin, Other Urinary, Pancreas, Prostate, Small Intestine, and StomachA Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KTN3379 in Adult Subjects with Advanced Tumors
Unknown SitesModular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 3 - MEK162 for Patients With RAS/RAF/MEK Activated Tumors

More Clinical Trials...

Edit Profile